Patient blood management: the solution to a double-edged sword?

YE Chee 1,2,3,4 *, MB, BS, FHKAM (Anaesthesiology), CS Lau 5,6, MB, ChB, FHKAM (Medicine)

1 Chief of Service, Department of Anaesthesia, Queen Mary Hospital
2 Vice President, Society of Anaesthetists in Hong Kong
3 Honorary Clinical Associate Professor, The University of Hong Kong, Hong Kong
4 Honorary Clinical Associate Professor, The Chinese University of Hong Kong, Hong Kong
5 Chair and Daniel CK Yu Professor in Rheumatology and Clinical Immunology, Department of Medicine, The University of Hong Kong, Hong Kong
6 President, Hong Kong Academy of Medicine, Hong Kong

* Corresponding author: cye254@ha.org.hk

In 1818, British obstetrician James Blundell successfully treated a patient diagnosed with postpartum haemorrhage with allogeneic blood transfusion. Transfusion medicine has since come a long way. The discovery of ABO blood groups in 1900 and Rh factor in 1939 by the Austrian immunologist Karl Landsteiner,1 the use of anticoagulants to preserve donor blood, and the implementation of donor blood screening tests for HBV (1970), HIV (1984), and HCV (1990), were all important milestones that helped to mitigate risks and enhance safety in blood transfusion practice. Today, allogeneic blood transfusion has become a mainstay in the treatment of anaemia2 and is among the most frequently prescribed life-saving therapies.3,4 Paradoxically, growing evidence shows that blood transfusion is associated with adverse patient outcomes.5 Blood transfusion is linked to increased infections and sepsis, length of hospital stay, and all-cause mortality.5,6

The sustainability of the donor blood supply is also at stake. Globally, the population aged ≥65 years is growing faster than all other age-groups, and the ratio is expected to increase from the current 1 in 11 (9%) to 1 in 6 (16%) by 2050.7,8 Because patients aged ≥65 years receive at least 50% of all blood transfusions,9,10 this 'inverted pyramid' in population growth means an imminent threat to the long-term blood supply. Critical shortages of allogeneic blood supply will soon ensue should the donation pattern and transfusion practices remain unchanged.9 The outcome impact and scarcity of supply call for a comprehensive approach in blood transfusion practice.

The term 'patient blood management’ (PBM) was first coined by an Australian haematologist, Professor James Isbister, in 2005 to advocate a shift in transfusion practice from a blood product focus to a patient-centred one.11 An observational study conducted by the Austrian group on perioperative blood use showed high predictability of preoperative anaemia, volume of perioperative blood loss, and transfusion threshold for allogeneic blood transfusion,12 which laid the groundwork for PBM to be built on. Goodnough et al took the initiative further by rationalising PBM interventions into three main pillars13,14:

1. detect and manage anaemia sufficiently early before major elective surgery;
2. exhaust all means to minimise iatrogenic blood loss; and
3. optimise anaemia tolerance to accommodate restrictive transfusion trigger.

Thus, PBM emerged as a multimodal, multi-disciplinary approach using evidence-based interventions to preserve or optimise patients’ red cell mass and to avoid allogeneic blood transfusion. It aims to ensure patient safety and improve clinical outcomes. The originally intended use of PBM was to target perioperative blood use in surgical patients. Over the past few years, PBM has been extended to include nonsurgical indications.15 The initiative was formally endorsed at the World Health Assembly in 2010.16

In the past decade, support for PBM has grown in the practice of transfusion medicine, and much effort has been invested clinically to implement PBM. While PBM is most effective as an integrated part of a multidisciplinary clinical pathway,17 often only a single intervention or a pillar of PBM is implemented by an individual department in a piecemeal manner. Few institutions run PBM as a comprehensive hospital-wide programme that encompasses all measures guided by a transfusion algorithm.18 Barriers to wider implementation of PBM include clinicians’ resistance to change, lack of engagement of health authorities and policy makers, lack of resources, difficulties in translating evidence-based guidelines into feasible clinical practice, and an effective outcome audit.17-19 In 2008, the Western Australia Department of Health initiated a 5-year project to implement a health system–wide PBM
programme that involved re-engineering of clinical processes and change management at all levels of the healthcare organisation. The successful initiative led to significant reductions in blood transfusion, hospital acquired infections, in-hospital mortality, hospital length of stay, and readmission rate. The reduction in transfusion alone was translated into a saving of over AU$18 million from product procurement and AU$80 million from activity-based savings.\textsuperscript{17,18} The initiative showcased the successful implementation of a PBM programme that required engagement and participation of regulatory bodies and health authorities in addition to clinical leadership, fund allocation, and technology support.\textsuperscript{18,20,22} Of course, the economic burden of blood transfusion and hence the cost savings resulted give added value to a well-run PBM programme.\textsuperscript{18,20-22}

The 2018 Frankfurt Consensus Conference made 10 clinical and 12 research recommendations on preoperative anaemia management, transfusion thresholds in adults, and implementation of PBM programmes.\textsuperscript{23} The panel found a paucity of strong thresholds in adults, and implementation of PBM on preoperative anaemia management, transfusion alone was translated into a saving of AU$80 million from activity-based savings.\textsuperscript{17,18} The initiative showcased the successful implementation of a PBM programme that required engagement and participation of regulatory bodies and health authorities in addition to clinical leadership, fund allocation, and technology support.\textsuperscript{18,20,22} Of course, the economic burden of blood transfusion and hence the cost savings resulted give added value to a well-run PBM programme.\textsuperscript{18,20-22}

The 2018 Frankfurt Consensus Conference made 10 clinical and 12 research recommendations on preoperative anaemia management, transfusion thresholds in adults, and implementation of PBM programmes.\textsuperscript{23} The panel found a paucity of strong thresholds in adults, and implementation of PBM on preoperative anaemia management, transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21.


